Shameem Mahmood
YOU?
Author Swipe
View article: New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System Open
PURPOSE Outcomes in systemic light chain (AL) amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-…
View article: A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis Open
Not available.
View article: Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis Open
Summary Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra‐cellular deposition of light‐chain aggregates in critical organs. An immunomodulatory agent‐based quadruplet including anti‐CD38 therapy has not been in…
View article: Ethnicity in systemic AL amyloidosis may impact risk stratification
Ethnicity in systemic AL amyloidosis may impact risk stratification Open
Not available.
View article: Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System Open
Background: Systemic light chain (AL) amyloidosis is a protein misfolding disorder leading to progressive organ failure. Risk stratification has been robustly performed using cardiac biomarkers (troponin T and NT-proBNP) and light chain bu…
View article: Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis Open
Importance Cardiac amyloid infiltration is the key determinant of survival in systemic light-chain (AL) amyloidosis. Current guidelines recommend early switching therapy in patients with a nonoptimal or suboptimal response regardless of th…
View article: Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<scp>DVD</scp>) in relapsed/refractory light chain amyloidosis (<scp>AL</scp>) after initial Bortezomib‐based regime
Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (<span>DVD</span>) in relapsed/refractory light chain amyloidosis (<span>AL</span>) after initial Bortezomib‐based regime Open
Summary Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second‐line daratumumab‐bortezomib‐dexamethasone (DVD) in AL amyloidosis in bortezomib‐exposed patients. A total of 116 patien…
View article: Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients Open
Not available.
View article: Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis Open
Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry–based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC…
View article: Deep phenotyping of p.(<scp>V142I</scp>)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis?
Deep phenotyping of p.(<span>V142I</span>)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis? Open
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasingly recognized cause of heart failure. A total of 3–4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor fo…
View article: Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients
Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients Open
Introduction: Systemic light chain (AL) amyloidosis is a rare incurable disorder caused by extracellular deposition of misfolded light chain protein fibrils causing organ dysfunction. Cardiac involvement is present in approximately two thi…
View article: High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis
High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis Open
Introduction: Systemic AL amyloidosis, a rare incurable plasma cell disorder, has no approved treatments at relapse. Belantamab mafodotin is an antibody-drug conjugate which targets BCMA antigen approved for relapsed refractory myeloma. We…
View article: PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Disparities in patients enrolled into clinical trials compared to real world populations have been reported, particularly with underrepresentation of different rac…
View article: P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS
P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Survival in systemic AL amyloidosis depends on the severity of organ involvement and haematological response to treatment. Since cardiac involvement is the major d…
View article: Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience Open
High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) remains the standard consolidation in transplant eligible multiple myeloma (MM) patients. The timing between HDM administration and hematopoietic stem cell r…
View article: Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis Open
Aims To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that rel…
View article: Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis
Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis Open
Summary This study reports health‐related quality of life (HRQL) among newly‐diagnosed immunoglobulin light‐chain (AL) patients ( n = 914) treated with a bortezomib‐based regimen and its association with response depth and survival. Haemat…
View article: Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma Open
Not available.
View article: Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment Open
Aims To assess the ability of cardiovascular magnetic resonance (CMR) to (i) measure changes in response to chemotherapy; (ii) assess the correlation between haematological response and changes in extracellular volume (ECV); and (iii) asse…
View article: The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre Open
AApoAI amyloidosis is a slowly progressive disease that is challenging to diagnose. The outcomes of transplantation are encouraging and graft survival is excellent.
View article: Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors Open
Background Plasma cell disorders (PCD) are at risk of inadequate immune responses to COVID-19 vaccines due to recognised humoral and cellular immune dysfunction which is multi-factorial and related to host and disease factors. With an esti…
View article: Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors Open
We read with interest Avivi et al.1 evaluating humoral response to two doses of BNT162b2 mRNA vaccine in multiple myeloma (MM) at manufacturer's dosing interval. Suboptimal response to one2-4 and both doses5 of coronavirus disease 2019 (CO…
View article: Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light‐chain (AL) amyloidosis
Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light‐chain (AL) amyloidosis Open
Summary Renal risk stratification in systemic immunoglobulin light‐chain (AL) amyloidosis is according to estimated glomerular filtration rate (eGFR) and urinary protein creatinine ratio (uPCR), the latter attributed to glomerular dysfunct…
View article: Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis Open
Aims Cardiac involvement, a major determinant of prognosis in AL (light-chain immunoglobulin) amyloidosis, is characterized by an impairment of longitudinal strain (LS%). We sought to evaluate the utility of LS% in a prospectively observed…
View article: Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy Open
Patients with multiple myeloma and related plasma cell disorders (PCD) are considered extremely vulnerable to SARS-CoV-2 infection due to disease-related impaired humoral and cellular immunity as well as receipt of immunosuppressive therap…
View article: Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma Open
Background The treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now repr…
View article: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib Open
The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here we report the impact of speed of response in a cohort of A…